Surveillance report supports safety of JYNNEOS vaccine for mpox prevention

A surveillance report from the United States examined the safety of the JYNNEOS vaccine for preventing mpox. The report type is described as surveillance, but key methodological details such as the study phase, specific population, sample size, comparator, follow-up duration, and primary outcome were not reported. No numerical results, effect sizes, or statistical measures were provided for the main finding that surveillance supports the vaccine's safety.

No safety data on adverse events, serious adverse events, discontinuations, or tolerability were reported in the input. The report did not list specific limitations, and funding or conflict of interest information was not provided.

The practice relevance and causality implications were also not reported. Given the lack of detailed data, this report should be viewed as an initial signal from safety monitoring systems rather than definitive evidence. Clinicians should await more detailed studies with transparent methodology and quantitative safety outcomes to fully assess the vaccine's risk-benefit profile.